Publications

Read the ASGCT-Citeline 2025 Q2 Landscape Analysis Field Report

Read + download the report - August 01, 2025

In Q2, three new therapeutics were approved and the number of gene therapy programs continued to climb.

The second quarterly report of 2025 from ASGCT and Citeline is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

  • FDA approved Zevaskyn for recessive dystrophic epidermolysis bullosa (RDEB) and mNexspike for COVID-19

  • In China, the country’s first gene therapy for hemophilia B was approved

  • Sixty-four percent of the 80 gene therapy trials initiated were for oncology indications, the highest proportion of the past year

 Read + Download the Full Report

Related Articles

Annual Meeting 2025

Now Available: 28th Annual Meeting Abstracts

Read + download the latest CGT reserach - April 28, 2025
Publications

Read the ASGCT-Citeline 2025 Q1 Landscape Analysis Field Report

Read + download the latest report - April 17, 2025
Publications

Read ASGCT's 2023 Q4 Landscape Analysis Field Report

Read & download the full report - January 12, 2024
Publications

Read ASGCT's 2023 Q2 Landscape Analysis Field Report

July 13, 2023